7 patents currently held
7 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
The next term ends in Apr 2039. from the record
Of the 7 now held by other companies, 4 name AbbVie Biotechnology Ltd. as their current owner, and 3 more name another party. Each row says which.
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
0
Ending by 2030
Apr 2039
Next term end
3
Patent families
When these terms end
Held patents by the year their term ends
notable patents
all others
Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size.
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Ends Apr 2039 · High confidence
Also notable
Ends Oct 2040 · High confidence
Also notable
Ends Nov 2042 · High confidence
Pyridazinones as PARP7 Inhibitors
US 10,550,105
The most cited patent in this portfolio, cited by 12 later US patents, top 25% of utility patents granted in 2020 in our data. Protection runs to 2039.
Pyridazinones as PARP7 Inhibitors
US 11,691,969
Cited by 3 later US patents, top 25% of utility patents granted in 2023 in our data. Protection runs to 2040.
Solid Forms of a PARP7 Inhibitor
US 12,371,421
Granted 2025. Too new for citation comparison; protection runs to 2042.
Formerly held, still cited
Notable
Ends Jul 2040 · High confidence
Cited by 7 later US patents, top 25% of utility patents granted in 2022 in our data. Protection runs to 2040.
now held by Boehringer Ingelheim International GmbH
Also notable
Ends Aug 2039 · High confidence
Cited by 8 later US patents, top 25% of utility patents granted in 2022 in our data. Protection runs to 2039.
now held by AbbVie Biotechnology Ltd.
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Jan 4, 2027The maintenance fee for Pyridazinones as PARP7 Inhibitors (US 11,691,969) comes due Jan 4, 2027. Unpaid by Jul 6, 2027, it lapses early.
- 1 fee due Aug 4, 2027The maintenance fee for Pyridazinones as PARP7 Inhibitors (US 10,550,105) comes due Aug 4, 2027. Unpaid by Feb 4, 2028, it lapses early.
Recent changes
- Nov 9Assignment recorded on 1 record: Ribon Therapeutics, Inc. to Nerviano Medical Sciences, Inc. Recorded Nov 9, 2026, executed Aug 7, 2024. Conveyance as recorded: Assignment of Assignor's Interest. A recorded assignment is a filed document, not a statement of current ownership. Reel 76685, frame 434.
What they patent
Grouped by real patent family, largest first, labeled by the earliest filing in each. No technology classification is inferred from titles.
| Pyridazinones as PARP7 Inhibitors (2019) | 4 in force | to Apr 2039 |
| Pyridazinones as PARP7 Inhibitors (2020) | 2 in force | to Nov 2040 |
| Solid Forms of a PARP7 Inhibitor | 1 in force | to Nov 2042 |
Patents held now
Soonest term end first.
Showing 1 to 7 of 7
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 10,550,105 | Pyridazinones as PARP7 Inhibitors In force · High confidence | In force | High confidence | |
| US 10,870,641 | Pyridazinones as PARP7 Inhibitors In force · High confidence | In force | High confidence | |
| US 11,014,913 | Pyridazinones as PARP7 Inhibitors In force · High confidence | In force | High confidence | |
| US 11,566,020 | Pyridazinones as PARP7 Inhibitors In force · High confidence | In force | High confidence | |
| US 11,691,969 | Pyridazinones as PARP7 Inhibitors In force · High confidence | In force | High confidence | |
| US 12,617,782 | Pyridazinones as PARP7 Inhibitors In force · Medium confidence | In force | Medium confidence | |
| US 12,371,421 | Solid Forms of a PARP7 Inhibitor In force · High confidence | In force | High confidence |
Also on record, not counted in the 7: 7 patents in force now held by others · 7 applications pending · 7 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.